Is there an association between hormone replacement therapy and breast cancer?

Journal of Women's Health

Volumn 7, Issue 10, 1998, Pages 1231-1246

  Creasman, William T ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

BREAST CANCER; CANCER RISK; ESTROGEN THERAPY; FEMALE; HUMAN; MENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0032457570     PISSN: 10597115     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.1998.7.1231     Document Type: Review

References (72)

1. Peskin JL, Utian WH. Ambulatory screening for postmenopausal patients: What is needed, and when? Menopause Manage 1993;2:19, 31
2. Andrews WC. Continuous combined estrogen/progestin hormone replacement therapy. Clin Ther 1995;17:812.
3. Griffing GT, Allen SH. Estrogen replacement therapy at menopause. Postgrad Med 1994;96:131.
4. Committee on Technical Bulletins. Hormone replacement therapy. Washington, DC: American College of Obstetrics and Gynecology, 1992. ACOG Technical Bulletin No. 156.
5. Kronenberg F. Hot flashes: Phenomenology, quality of life, and search for treatment options. Exp Gerontol 1994;29:319.
6. American Association of Clinical Endocrinologists. AACE clinical practice guidelines for the prevention and treatment of postmenopausal osteoporosis. Endocr Pract 1996;2:155.
7. Barrett-Connor E. Risks and benefits of replacement estrogen. Annu Rev Med 1992;43:239.
8. Smith HO, Krammerer-Doak DN, Barbo DM, Sarto GE. Hormone replacement therapy in the menopause: A pro opinion. CA 1996;46:343.
9. Oldenhave A, Jaszmann LJ, Haspels AA, Everaerd WT. Impact of climacteric on well-being. A survey based on 5213 women 39 to 60 years old. Am J Obstet Gynecol 1993;168:772.
10. Ditkoff EC, Crary WG, Cristo M, Lobo RA. Estrogen improves psychological function in asymptomatic postmenopausal women. Obstet Gynecol 1991;78:991.
11. Limouzin-Lamothe M-A, Marion N, Joyce CRB, Le Gal M. Quality of life after the menopause: Influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170:618.
12. Armstrong EP. Pharmacoeconomic analysis of hormone replacement therapy - Implications for managed care. J Managed Care Pharm 1997;3:200.
13. Andrews WC. The transitional years and beyond. Obstet Gynecol 1995;85:1.
14. Gibaldi M. Hormone replacement therapy: Estrogen after menopause. Pharmacotherapy 1996; 16:366.
15. Gambrell DR Jr. Management of hormone replacement therapy side effects. Menopause 1994;1:67.
16. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997;277:1140.
17. Lerner S. Counseling the patient at menopause concerning hormone replacement therapy. Menopause 1995;2:175.
18. Assessing the odds [Editorial]. Lancet 1997;350:1563.
19. American Heart Association. Women and cardiovascular diseases. In: Cardiovascular disease in women. Dallas, TX: American Heart Association, 1997;5.
20. Cobleigh MA, Berris RF, Bush T, et al. Estrogen replacement therapy in breast cancer survivors. JAMA 1994;272:540.
21. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993;15:66.
22. Henrich JB. The postmenopausal estrogen/breast cancer controversy. JAMA 1992;268:1900.
23. Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996;7:449.
24. Newcomb PA, Longnecker MP, Storer BE, et al. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 1995;142:788.
25. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994;5:491.
26. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137.
27. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in. postmenopausal women. Ann Intern Med 1992;117:1016.
28. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985.
29. Armstrong BK. Oestrogen therapy after the menopause - Boon or bane? Med J Aust 1988;148:213.
30. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473.
31. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67.
32. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992;79:286.
33. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321:293.
34. Ewertz M. Hormone therapy in the menopause and breast cancer risk - A review. Maturitas 1996;23:241.
35. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047.
36. Sellers TA, Mink PJ, Cerhan JR, et al. The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973.
37. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332:1589.
38. LaCroix AZ, Burke W. Breast cancer and hormone replacement therapy [Commentary]. Lancet 1997;350: 1042.
39. Stanford JL, Thomas DB. Exogenous progestins and breast cancer. Epidemiol Rev 1993;15:98.
40. Nachtigall MJ, Smilen SW, Nachtigall RD, Nachtigall RD, Nachtigall RH, Nachtigall LE. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992;80:827.
41. Adami H-O, Persson I. Hormone replacement and breast cancer. A remaining controversy? [Editorial]. JAMA 1995;274:178.
42. Rossouw JE, Finnegan LP, Harlan WR, Pinn VW, Clifford C, McGowan JA. The evolution of the Women's Health Initiative: Perspectives from the NIH. J Am Med Wom Assoc 1995;50:50.
43. Vickers MR, Wilkes HC, Meade TW. Hormone replacement therapy and cardiovascular disease: The case for a randomized controlled trial. Ciba Found Symp 1995;191:150.
44. Creasman WT. Estrogen replacement therapy: Is previously treated cancer a contraindication? Obstet Gynecol 1991;77:308.
45. DiSaia PJ. Hormone-replacement therapy in patients with breast cancer. Cancer 1993;71:1490.
46. Dupont WD, Page DL, Rogers LW, Parl FF. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989;63:948.
47. Eden JA, Bush T, Nand S, Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause 1995;2:67.
48. DiSaia PJ, Odicino F, Grosen EA, et al. Hormone replacement therapy in breast cancer [Letter]. Lancet 1993;342:1232.
49. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769.
50. Ettinger B, Friedman GD, Bush T, Quesenberry CP. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996; 87:6.
51. Henderson VW, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75.
52. Folsom AR, Mink PJ, Sellers TA, Hong C-P, Zheng W, Potter JD. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995;85:1128.
53. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Results from a prospective study in a defined, homogeneous community. Am J Epidemiol 1988;128:606.
54. Bergkvist L, Adami H-O, Persson I, Bergström R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;130:221.
55. Vassilopoulou-Sellin R, Theriault RL. Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. J Natl Cancer Inst Monogr 1994;16:153.
56. LeLorier J, Grégoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med 1997;337:536.
57. Spitzer WO. Meta-meta-analysis: Unanswered questions about aggregating data [Editorial]. J Clin Epidemiol 1991;44:103.
58. Hol T, Cox MB, Bryant HU, Draper MW. Selective estrogen receptor modulators and postmenopausal women's health. J Women's Health 1997;6:523.
59. Jordan VC. After menopause: Tamoxifen and other new prevention maintenance therapies [Editorial]. J Women's Health 1997;6:257.
60. Geelhoed E, Harris A, Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health 1994;18:153.
61. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA 1996;276: 1389.
62. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122:9.
63. Nassén T, Persson I, Adami H-O, Bergström R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. Ann Intern Med 1990;113:95.
64. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PWF, Anderson JJ. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141.
65. Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995;87:517.
66. Newcomb PA, Storer BE. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst 1995;87:1067.
67. Kampman E, Potter JD, Slattery ML, Caan BJ, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: A multicenter, case-control study in the United States. Cancer Causes Control 1997;8:146.
68. Kawas C, Resnick S, Morrison A, et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517.
69. Tang M-X, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429.
70. Mortel KF, Meyer JS. Lack of postmenopausal estrogen replacement therapy and the risk of dementia. J Neuropsychiatry Clin Neurosci 1995;7;334.
71. Henderson VW, Paganini-Hill A, Emanuel CK, Dunn ME, Buckwalter JG. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects. Arch Neurol 1994;51:869.
72. Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996;114:545.